Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1535 studies found for:    TNF
Show Display Options
Rank Status Study
21 Recruiting Biomarkers of Anti-TNF Treatment in IBD
Condition: Inflammatory Bowel Diseases
Interventions: Biological: Infliximab;   Biological: Adalimumab
22 Unknown  Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy
Condition: Rheumatoid Arthritis
Intervention:
23 Not yet recruiting Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy
Condition: Inflammatory Bowel Disease
Intervention:
24 Completed 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy
Condition: Juvenile Idiopathic Arthritis
Intervention: Biological: anti-TNF
25 Completed Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma
Conditions: Hepatitis B;   Hepatocellular Carcinoma;   Chronic Liver Disease
Intervention: Genetic: Polymorphism of IL-1 beta and TNF-alpha
26 Completed Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients
Condition: Crohn's Disease
Interventions: Biological: TNF Kinoid;   Biological: WFI
27 Completed L19TNFα in Patients With Advanced Solid Tumors
Conditions: Solid Tumors;   Colorectal Cancer
Intervention: Drug: L19TNFa
28 Completed An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Infliximab 10 mg/kg;   Drug: Infliximab 5 mg/kg;   Drug: Placebo
29 Completed Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Conditions: Recurrent Melanoma;   Stage III Melanoma
Interventions: Drug: isolated limb perfusion;   Drug: melphalan;   Biological: recombinant tumor necrosis factor family protein;   Other: pharmacological study;   Other: laboratory biomarker analysis
30 Recruiting Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease;   Ulcerative Colitis;   Crohn's Disease;   Indeterminate Colitis
Intervention:
31 Active, not recruiting Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.
Conditions: Psoriasis Vulgaris;   Metabolic Syndrome
Intervention:
32 Recruiting Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Conditions: Chronic Hepatitis B;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis;   Juvenile Idiopathic Arthritis
Interventions: Drug: Entecavir;   Drug: Placebo
33 Recruiting Escape II Myocardium
Condition: Rheumatoid Arthritis
Interventions: Drug: Triple Therapy;   Drug: TNF inhibitors
34 Unknown  The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Conditions: Rheumatoid Arthritis;   Crohn's Disease;   Ankylosing Spondylitis;   Psoriasis
Intervention: Drug: TNF-alpha antagonists
35 Completed Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
Conditions: Coccidioidomycosis;   Rheumatoid Arthritis
Intervention:
36 Unknown  Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis
Condition: SPONDYLOARTHRITIS
Intervention: Drug: Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
37 Completed A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients
Condition: HIV Infections
Intervention: Drug: Tumor Necrosis Factor soluble receptor-immunoadhesin complex
38 Completed An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Infliximab 5 mg/kg;   Drug: Infliximab 10 mg/kg;   Drug: Infliximab 20 mg/kg;   Drug: Placebo
39 Completed Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on Central Nervous System (CNS) Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?
Conditions: Inflammation;   Glucose Metabolism Disorders
Interventions: Biological: TNF-alpha;   Biological: Endotoxin
40 Unknown  Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient
Condition: RHEUMATOID ARTHRITIS
Interventions: Drug: Pred + Meth;   Drug: Anti TNF + Meth

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years